Advertisement
Advertisement
CSTL
Castle Biosciences, Inc. Common Stock
24.62
USDSponsored
+0.25
+1.03%
Apr 15, 16:00 UTC -4
Closed
Pre-Market
24.48
-0.14
-0.56%
CSTL Earnings Reports
Positive Surprise Ratio
CSTL beat 21 of 27 last estimates.
78%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$81.00M
/-$0.49
Implied change from Q4 25 (Revenue/ EPS)
-6.90%
/+512.50%
Implied change from Q1 25 (Revenue/ EPS)
-7.94%
/+145.00%
Castle Biosciences, Inc. Common Stock earnings per share and revenue
On Feb 26, 2026, CSTL reported earnings of -0.08 USD per share (EPS) for Q4 25, beating the estimate of -0.29 USD, resulting in a 72.60% surprise. Revenue reached 87.01 million, compared to an expected 80.63 million, with a 7.91% difference. The market reacted with a +0.81% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 9 analysts forecast an EPS of -0.49 USD, with revenue projected to reach 81.00 million USD, implying an increase of 512.50% EPS, and decrease of -6.90% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Nurix Therapeutics, Inc. Common stock
Report Date
Apr 08, 2026 For Q1 26
Estimate
-$0.76
Actual
-$0.79
Surprise
-2.68%
NovaBridge Biosciences - ADR
Report Date
Apr 07, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.28
Surprise
-421.58%
Scilex Holding Company Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$0.47
Actual
-$2.21
Surprise
-360.99%
Lexaria Bioscience Corp. Common Stock
Report Date
Apr 13, 2026 For Q2 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+38.08%
Quince Therapeutics, Inc. Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$1.92
Actual
-$7.10
Surprise
-268.68%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
FAQ
What were Castle Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Castle Biosciences, Inc. Common Stock reported EPS of -$0.08, beating estimates by 72.6%, and revenue of $87.01M, 7.91% above expectations.
How did the market react to Castle Biosciences, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 0.81%, changed from $39.34 before the earnings release to $39.66 the day after.
When is Castle Biosciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Castle Biosciences, Inc. Common Stock's next earnings report?
Based on 9
analysts, Castle Biosciences, Inc. Common Stock is expected to report EPS of -$0.49 and revenue of $81.00M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement